Drug maker Boehringer Ingelheim enjoyed some gains during the first six months of 2012, but the next six months may be a bit rocky. “The economic headwind from the sovereign debt crisis in southern Europe and the continued weak economic growth in the USA make the business environment increasingly difficult for the pharmaceutical industry,” Andreas Barner, chairman of the board, said in a statement. Barner added that the economic and financial strains have hampered the launches of two of its newer medications – the blood thinner Pradaxa and the diabetes drug Tradjenta. Pradaxa alone brought in $678 million in sales ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.